Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

NEW YORK: Novel Treatment for Gonorrhea Acts Like a 'Live Vaccine,' Prevents Reinfection


NEW YORK: STDs Aids Weekly Plus

Medical Xpress (09.18.2013) :: By Ellen Goldblum Researchers at startup biotech company TherapyX, Inc., have developed a new gonorrhea treatment that acts like a vaccine to prevent reinfection. According to Michael W. Russell, PhD, professor of microbiology and immunology at the University at Buffalo (UB)—The State University of New York’s School of Medicine and Biomedical Sciences, and colleagues, the gonorrhea infection was able to inhibit certain adaptive immune responses, which was part of the reason why individuals could be reinfected numerous times. Russell explained that the gonococcal infection controlled the immune system and elicited responses that the bacterium could fight and suppressed responses that it could not fight. Russell then thought that NanoCap, the anti-cancer therapy that his colleague Nejat K. Egilmez, PhD, professor of microbiology and immunology at UB, had developed could help. NanoCap is a sustained release nanoparticle treatment using Interleukin (IL)-12 to stimulate an immune response against tumors that usually suppress immunity. The researchers used the NanoCap technology in the fight against gonorrhea. When they introduced IL-12 microspheres intravaginally in mice, the mice experienced a precise adaptive immune response by developing antibodies specific to the gonorrhea bacteria and clearing the infection in days. The researchers’ attempt to reinfect the mice a month later was unsuccessful, as the mice were able to resist reinfection. The researchers planned to investigate whether the immunity could last longer than a month in mice and to test the treatment in humans. TherapyX, Inc., cofounded by Egilmez, received a $300,000 small business grant to develop the technology to treat and prevent gonorrhea, and UB’s Office for Science Technology Transfer and Economic Outreach has filed for patent protection. The full report, “Enhancement of Adaptive Immunity to Neisseria gonorrhoeae by Local Intravaginal Administration of Microencapsulated Interleukin 12,” was published online in the Journal of Infectious Diseases (2013; doi: 10.1093/infdis/jit354).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in September 18, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.